Press Releases April 30, 2026 04:00 PM

Nephros Schedules First Quarter 2026 Financial Results Conference Call

Nephros announces Q1 2026 financial results release and conference call scheduled for May 7, 2026.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
NEPH

Nephros, Inc., a water technology company specializing in filtration solutions for medical and commercial markets, will release its Q1 2026 financial results after market close on May 7, 2026. The company will host a conference call the same day to discuss the results, providing details for participation and replay access.

Nephros Schedules First Quarter 2026 Financial Results Conference Call
NEPH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Nephros will file its first-quarter 2026 financial results on May 7, 2026, after market close.
  • A conference call to discuss the financial results is scheduled for the same day at 4:30pm ET with dial-in details provided.
  • Nephros operates in water filtration technology serving medical and commercial markets, focusing on water safety and quality.

SOUTH ORANGE, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its first-quarter financial results on Thursday, May 07, 2026 after market close and will host a conference call that same day at 4:30pm ET.

Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285

Upon joining, please ask to be joined into the Nephros conference call.

An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

Alternatively, a replay of the call may be accessed until May 14, 2026 at 1-855-669-9658
or 1-412-317-0088 for international callers and entering replay access code: 1329051.

About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within medical and commercial markets, offering both proactive and emergency solutions for water management.

For more information about Nephros, please visit us at nephros.com.

Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
robert.banks@nephros.com


Risks

  • Financial results could reveal performance weaker than market expectations, potentially impacting stock price.
  • Economic or regulatory developments affecting water technology or filtration industries may influence future company performance.
  • Market conditions at the time of the earnings report could cause volatility despite the scheduled release and call.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026